ArticleJournal of computer-aided molecular design2026
Flexibility-driven design of etoposide derivatives targeting Daam1: a thermodynamics-guided strategy against breast cancer metastasis.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Balancing molecular flexibility and rigidity remains a key challenge in rational drug design. Here, the Daam1 formin homology 2 (FH2) domain, a regulator of tumor metastasis, was used as a model to investigate the role of flexible side chains in targeted inhibition. Molecular docking, micro-scale thermophoresis, and molecular dynamics simulations showed that the flexible peptide thymopentin binds Daam1 more stably than etoposide through sustained interactions with Arg692 and Asn695. Guided by these insights, the 4' position of etoposide was optimized using free energy perturbation combined with enhanced sampling MD. Two derivatives, V2 and V3, exhibited improved binding free energies. In vitro assays demonstrated that V2 and V3 enhanced inhibition of breast cancer cell migration and reduced Daam1 expression to approximately half of the level observrd with etoposide. This study establishes a flexibility-driven optimization strategy and highlights FEP-enhanced MD as a robust framework for rational drug design.
Indexed as
Identifiers
42213223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.